285 related articles for article (PubMed ID: 33526518)
1. Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions.
Oldfield K; Jayasinghe R; Niranjan S; Chadha S
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33526518
[TBL] [Abstract][Full Text] [Related]
2. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Leader R; Cowen J; Rajeev SP
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
[TBL] [Abstract][Full Text] [Related]
4. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis.
Soni P; Kumar V; Saradna A; Kupfer Y
Am J Ther; 2018; 25(6):e740-e741. PubMed ID: 29746292
[No Abstract] [Full Text] [Related]
6. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
Cao Y; Afzal MZ; Shirai K
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
[TBL] [Abstract][Full Text] [Related]
7. Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors.
Isaacs M; Tonks KT; Greenfield JR
Intern Med J; 2017 Jun; 47(6):701-704. PubMed ID: 28580740
[TBL] [Abstract][Full Text] [Related]
8. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
9. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
10. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
11. Low carbohydrate diet while taking dapagliflozin: A case report and review of literature.
Paul N; Jonklaas J
Diabetes Metab Syndr; 2021; 15(1):361-363. PubMed ID: 33517150
[No Abstract] [Full Text] [Related]
12. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
Goff CB; Plaxe SC; White W; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
[TBL] [Abstract][Full Text] [Related]
16. A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors.
Bashir J; Nalla P; Peter R; Bain SC; Chudleigh R
Diabetes Obes Metab; 2018 Jul; 20(7):1800-1801. PubMed ID: 29493069
[No Abstract] [Full Text] [Related]
17. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
Fujiwara M; Shimizu M; Okano T; Maejima Y; Shimomura K
Front Public Health; 2023; 11():1264056. PubMed ID: 38106883
[TBL] [Abstract][Full Text] [Related]
19. Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy.
Giblin GT; Dennehy C; Featherstone H; Clarke R; Murphy L; Timlin D; O'Keane C; Mulligan N; Kelly CM; Joyce E
Circ Heart Fail; 2021 Feb; 14(2):e007524. PubMed ID: 33478241
[No Abstract] [Full Text] [Related]
20. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
